Work

Cost-effectiveness analysis of atezolizumab plus bevacizumab and chemotherapy for the treatment of metastatic, persistent, or recurrent cervical cancer (BEATcc)

Year: 2024

Type: article

Source: Expert Review of Pharmacoeconomics & Outcomes Research

DOI: 10.1080/14737167.2024.2422465

Authors: Yixiao Zhu, Fenghao Shi, Huiting Lin, Yingdan Cao, Hongbin Yi, Sheng Han, Xiaoxia Wei

Institutions: Fujian Medical University, Fujian Provincial Hospital, Fuzhou University, Peking University

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Fujian Provincial Health Technology Project

Awards: G440364694, G7121951965

OpenAlex ID: W4403825893

FWCI: 1.446

Cites: 29

Cited by: 4

Related to: 10